Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 10 May 1985:
Vol. 228. no. 4700, pp. 737 - 740
DOI: 10.1126/science.2986288
Prev | Table of Contents | Next

Articles

Science, Vol 228, Issue 4700, 737-740
Copyright © 1985 by American Association for the Advancement of Science

articles

Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice

KJ Cremer, M Mackett, C Wohlenberg, AL Notkins, and B Moss

In humans, herpes simplex virus causes a primary infection and then often a latent ganglionic infection that persists for life. Because these latent infections can recur periodically, vaccines are needed that can protect against both primary and latent herpes simplex infections. Infectious vaccinia virus recombinants that contain the herpes simplex virus type 1 (HSV-1) glycoprotein D gene under control of defined early or late vaccinia virus promoters were constructed. Tissue culture cells infected with these recombinant viruses synthesized a glycosylated protein that had the same mass (60,000 daltons) as the glycoprotein D produced by HSV-1. Immunization of mice with one of these recombinant viruses by intradermal, subcutaneous, or intraperitoneal routes resulted in the production of antibodies that neutralized HSV-1 and protected the mice against subsequent lethal challenge with HSV-1 or HSV-2. Immunization with the recombinant virus also protected the majority of the mice against the development of a latent HSV-1 infection of the trigeminal ganglia. This is the first demonstration that a genetically engineered vaccine can prevent the development of latency.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Effective Vaccination against Long-Term Gammaherpesvirus Latency.
S. A. Tibbetts, J. S. McClellan, S. Gangappa, S. H. Speck, and H. W. Virgin IV (2003)
J. Virol. 77, 2522-2529
   Abstract »    Full Text »    PDF »
Vaccine-Induced Serum Immunoglobin Contributes to Protection from Herpes Simplex Virus Type 2 Genital Infection in the Presence of Immune T Cells.
L. A. Morrison, L. Zhu, and L. G. Thebeau (2001)
J. Virol. 75, 1195-1204
   Abstract »    Full Text »
Attenuated Modified Vaccinia Virus Ankara Can Be Used as an Immunizing Agent under Conditions of Preexisting Immunity to the Vector.
J. C. Ramírez, M. M. Gherardi, D. Rodríguez, and M. Esteban (2000)
J. Virol. 74, 7651-7655
   Abstract »    Full Text »
T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant.
P. Earl, B Moss, R. Morrison, K Wehrly, J Nishio, and B Chesebro (1986)
Science 234, 728-731
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)